Linked Life Data

20616206

Source:http://linkedlifedata.com/resource/pubmed/id/20616206

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20616206rdf:typepubmed:Citationlld:pubmed
pubmed-article:20616206lifeskim:mentionsumls-concept:C0010620lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1373059lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C0439097lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:20616206lifeskim:mentionsumls-concept:C1547348lld:lifeskim
pubmed-article:20616206pubmed:issue2lld:pubmed
pubmed-article:20616206pubmed:dateCreated2010-9-17lld:pubmed
pubmed-article:20616206pubmed:abstractTextThe unexpected observation of a hyperglycemic effect of some tricycle-based delta opioid receptor (DOR) agonists led to a series of studies to better understand the finding. Single administration of two novel tricyclic DOR agonists dose dependently elevated rat plasma glucose levels; 4-week toxicology studies confirmed the hyperglycemic finding and further revealed pancreatic ?-cell hypertrophy, including vacuole formation, as well as bone dysplasia and Harderian gland degeneration with regeneration. Similar diabetogenic effects were observed in dog. A review of the literature on the antiserotonergic and antihistaminergic drug cyproheptadine (CPH) and its metabolites revealed shared structural features as well as similar hyperglycemic effects to the present series of DOR agonists. To further evaluate these effects, we established an assay measuring insulin levels in the rat pancreatic ?-cell-derived RINm5F cell line, extensively used to study CPH and its metabolites. Like CPH, the initial DOR agonists studied reduced RINm5F cell insulin levels in a concentration-dependent manner. Importantly, compound DOR potency did not correlate with the insulin-reducing potency. Furthermore, the RINm5F cell insulin results correlated with the diabetogenic effect of the compounds in a 5-day mouse study. The RINm5F cell insulin assay enabled the identification of aryl-aryl-amine DOR agonists that lacked an insulin-reducing effect and did not elevate blood glucose in repeated dosing studies conducted over a suprapharmacologic dose range. Thus, not only did the RINm5F cell assay open a path for the further discovery of DOR agonists lacking diabetogenic potential but also it established a reliable, economical, and high-throughput screen for such potential, regardless of chemotype or target pharmacology. The present findings also suggest a mechanistic link between the toxicity observed here and that underlying Wolcott-Rallison Syndrome.lld:pubmed
pubmed-article:20616206pubmed:languageenglld:pubmed
pubmed-article:20616206pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:citationSubsetIMlld:pubmed
pubmed-article:20616206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20616206pubmed:statusMEDLINElld:pubmed
pubmed-article:20616206pubmed:monthOctlld:pubmed
pubmed-article:20616206pubmed:issn1096-0929lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:CaiChaozhongClld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:ZhangSui-PoSPlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:LinLingLlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:BrandtMichael...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:McDonnellMark...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:DaxScott LSLlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:LenhardJames...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:CoddEllen EEElld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:McMillianMich...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:CarsonJohn...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:BakerJudithJlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:FloresChristo...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:BryantStewart...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:KemmererMicha...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:McNallyJames...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:ColburnRaymon...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:StoneDennis...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:LeoneAngeliqu...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:CooganTimothy...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:ChevalierKris...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:DecorteBartBlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:LegrandEdmund...lld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:MabusJohn RJRlld:pubmed
pubmed-article:20616206pubmed:authorpubmed-author:WangCharles...lld:pubmed
pubmed-article:20616206pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20616206pubmed:volume117lld:pubmed
pubmed-article:20616206pubmed:ownerNLMlld:pubmed
pubmed-article:20616206pubmed:authorsCompleteYlld:pubmed
pubmed-article:20616206pubmed:pagination493-504lld:pubmed
pubmed-article:20616206pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:meshHeadingpubmed-meshheading:20616206...lld:pubmed
pubmed-article:20616206pubmed:year2010lld:pubmed
pubmed-article:20616206pubmed:articleTitleDiabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.lld:pubmed
pubmed-article:20616206pubmed:affiliationDrug Discovery, Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477, USA. ecodd@its.jnj.comlld:pubmed
pubmed-article:20616206pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20616206pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed